COREVIA PHARMA

Corevia Pharma is a French biotechnology company specializing in the development of next-generation radiopharmaceuticals for oncology. Founded in 2023 as a spin-off from the University of Burgundy, the company utilizes proprietary chelating technology to enhance the stability and efficacy of Targeted Alpha Therapies (TAT). Their platform is specifically designed to facilitate the use of potent alpha-emitting isotopes, such as Actinium-225, in treating various solid tumors. By optimizing the chemical link between the radioisotope and the targeting vector, Corevia aims to deliver highly precise radiation to cancer cells while minimizing off-target toxicity. The company's approach leverages decades of academic research in coordination chemistry to address current limitations in radioligand therapy. Corevia Pharma is currently advancing its pipeline through pre-clinical development with the goal of providing more potent and safer treatment options for cancer patients.